Navigation Links
New once-a-week treatment for type 2 diabetes developed by Mount Sinai researcher
Date:9/7/2008

(Toronto, ON, September 8, 2008) In a study published by the Lancet journal today, Toronto researcher Dr. Daniel Drucker reported that a new once-weekly treatment for type 2 diabetes could replace the more common twice-daily injection.

"Over two million Canadians have diabetes," said Dr. Daniel Drucker, clinician-scientist and Senior Investigator at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital. "There is currently no available therapy for type 2 diabetes that patients can receive once a week."

The new treatment, Exenatide once weekly is the first in a new class of long-acting medications that mimic the action of GLP-1 (glucagon-like peptide), a naturally occurring hormone that is produced in the gut after eating. The report compared outcomes for patients self-injecting Exenatide once weekly against results from the conventional 14 injections a week, as in the currently available version of the drug known as Exenatide (Byetta).

In an international multicentre 6-month clinical trial involving 300 eligible patients, 75 per cent of study subjects who received the once-weekly Exenatide got their diabetes under control as defined by reaching target glucose levels. Patients treated with Exenatide once weekly also experienced fewer side effects, had no increased risk of hypoglycemia (decrease in blood sugars) and saw reductions in body weight.

Dr. Drucker has studied the gut hormone GLP-1 for over 20 years. Multiple drugs based on GLP-1 action are under active clinical development, and the new once-weekly treatment is expected to undergo Canadian regulatory review as early as 2009.

"Biomedical research reaches patients and improves lives," said Dr. Jim Woodgett, Director of Research at the Samuel Lunenfeld Research Institute. "Dr. Drucker is a world-expert in the development of peptide hormone-based therapies for the treatment of human disease and this is an excellent example of moving discovery
'/>"/>

Contact: Nikki Luscombe
luscombe@lunenfeld.ca
416-586-4800 x2046
Samuel Lunenfeld Research Institute
Source:Eurekalert

Page: 1 2

Related biology news :

1. Landmark study opens door to new cancer, aging treatments
2. Common treatment to delay labor decreases preterm infants risk for cerebral palsy
3. UC Davis researchers define characteristics, treatment options for XXYY syndrome
4. Why a common treatment for prostate cancer ultimately fails
5. Biodegradable polymers show promise for improving treatment of acute inflammatory diseases
6. Childrens national co-leads nationwide study of landmark sickle cell treatment
7. Potatoes may hold key to Alzheimers treatment
8. Blood pressure response to daily stress provides clues for better hypertension treatment
9. Genes newly explained effect on height may change tumor disorder treatment
10. Songbirds may hold key to advances in treatment of brain degeneration
11. Treatment corrects severe insulin imbalance in animal studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) ... Sensor Market 2015-2019" report to their offering. ... major trend upcoming in this market is the increasing ... help in recording of patient data for quick and ...
(Date:12/11/2014)... 2014 Research and Markets , ... has announced the addition of the "Biometrics Market ... One major trend emerging in this ... technology, it is important to upgrade biometric solutions to ...
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences International ... has released a new series of digital telemetry ... toxicology researchers. M series, part of the PhysioTel™ ... the best possible physiologic data when incorporating functional ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... reliable indicators to predict that a person will develop type ... produced in the pancreas and is the hormone responsible for ... body, such as muscles. Insulin resistance is characterized by the ... a greater production of insulin by the pancreas. When the ...
... Cellmark Inc.,(Nasdaq: ORCH ), a leading worldwide provider of ... quarter of 2008. , Total ... $15.6 million for the third quarter of 2007. The decrease ... year ago was largely due,to lower revenues in the U.K. , ...
... ARLINGTON, Va., Nov. 18 Stanley, Inc.,(NYSE: ... professional,services to the U.S. federal government, today announced that ... International Corporation (NYSE: SAI ) awarded,a four-year, ... if,all three option years are exercised. With this award, ...
Cached Biology News:Researchers at IRB Barcelona produce more data on key genes in diabetes 2Researchers at IRB Barcelona produce more data on key genes in diabetes 3Orchid Cellmark Reports Third Quarter 2008 Financial Results 2Orchid Cellmark Reports Third Quarter 2008 Financial Results 3Orchid Cellmark Reports Third Quarter 2008 Financial Results 4Orchid Cellmark Reports Third Quarter 2008 Financial Results 5Orchid Cellmark Reports Third Quarter 2008 Financial Results 6Orchid Cellmark Reports Third Quarter 2008 Financial Results 7Orchid Cellmark Reports Third Quarter 2008 Financial Results 8Stanley to Continue Biometrics In-Service Engineering Support for U.S. Army 2Stanley to Continue Biometrics In-Service Engineering Support for U.S. Army 3
(Date:1/22/2015)... Pipette.com has added the Eppendorf Centrifuge ... of Eppendorf products. , The Eppendorf Centrifuge 5424/5424 R ... R and receive the following:, ,     Free ... Eppendorf Reference 2 ,     3 Free boxes ...
(Date:1/22/2015)... Switzerland (PRWEB) January 22, 2015 Selexis ... characterized mammalian Research Cell Banks (RCBs) used for drug ... Research Cell Banks will include Next-Generation Sequencing ... genetic architecture de-risks biologic manufacturing by ensuring the integrity ...
(Date:1/22/2015)... 22. 2015  Varian Medical Systems (NYSE: VAR ), ... for its commitment to sustainability with inclusion on a prestigious ... highest ranked healthcare equipment company among the Corporate Knights Global ... Economic Forum at Davos, Switzerland . ...
(Date:12/24/2014)... Md. , Dec. 24, 2014  United Therapeutics Corporation ... Inc. (NYSE: MDT ) has submitted a ... Administration (FDA) for the use of Medtronic,s SynchroMed ® ... developed catheter) for use with United Therapeutics, Remodulin ® ...
Breaking Biology Technology:Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Varian Honored Among World's 100 Most Sustainable Corporations 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... EXTON, Pa., March 2 Morphotek(R), Inc., a ... that it has commenced a,multi-centered Phase II study ... will evaluate MORAb-009, plus the chemotherapy drugs,pemetrexed and ... , The primary objective ...
... Calif., March 2 Pearl Therapeutics, a biopharmaceutical ... prevalent respiratory diseases, announced today the appointment of ... to attract a corporate leader with such an ... Ph.D., Venture Partner at 5AM Ventures and Executive ...
... in Managing Indoor and Outdoor AllergiesATLANTA and BRIDGEWATER, N.J., ... season quickly approaches, people living with nasal allergies should ... before they hit home. To help the nation,s estimated ... nasal allergy season, UCB and sanofi-aventis have enlisted a ...
Cached Biology Technology:Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma 2Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma 3Pearl Therapeutics Appoints Perry Karsen as Chief Executive Officer 2Video: Experts Unite to Help People Manage Spring Nasal Allergy Sneezin' 2Video: Experts Unite to Help People Manage Spring Nasal Allergy Sneezin' 3Video: Experts Unite to Help People Manage Spring Nasal Allergy Sneezin' 4Video: Experts Unite to Help People Manage Spring Nasal Allergy Sneezin' 5Video: Experts Unite to Help People Manage Spring Nasal Allergy Sneezin' 6
Sequencing and primer design rolled into one. Just give us your clone and a reference sequence, and we'll do the rest. Single-strand or double-strand coverage. Guaranteed results....
...
Anti-Wnt-2 Polyclonal Antibody Description: 100 g purified goat polyclonal antibody. Reacts with human/mouse/rat. Tested in Western blot/IP/IHC. Research Focus: signal transduction Storage...
... coating using advanced automated high throughput microplate processing equipment that ... also accommodate virtually any lot size of the following formats ... 8 and 12 well strips, ... 384 well microplate, ...
Biology Products: